Galcanezumab-Gnlm

Introduction Overview

Generic Name

galcanezumab-gnlm

Brand Name

Emgality

Dosage Form

prefilled pen (120 mg/mL), prefilled syringe (100 mg/mL, 120 mg/mL)

Drug Class

CGRP inhibitors

Pharmacokinetics

Absorption:
Galcanezumab, the active monoclonal antibody in Emgality, is administered subcutaneously and exhibits absorption characteristics typical of large molecule biologics. After subcutaneous injection, galcanezumab is absorbed slowly, reaching peak plasma concentrations (Cmax) approximately 5 days post-dose. The slow absorption contributes to the drug’s prolonged half-life, enabling monthly dosing intervals. The bioavailability of galcanezumab following subcutaneous administration is estimated to be approximately 50-80%, influenced by factors such as injection site and local blood flow.

Distribution:
As a monoclonal antibody, galcanezumab primarily remains within the vascular and interstitial spaces due to its large molecular size, resulting in a relatively low volume of distribution, estimated around 7.3 to 8.5 liters. The distribution is largely confined to extracellular fluids with limited penetration across the blood-brain barrier. Binding is specific to calcitonin gene-related peptide (CGRP), but galcanezumab circulates mostly unbound. There is no evidence of significant tissue accumulation. Plasma protein binding is minimal, as galcanezumab does not extensively interact with other plasma proteins.

Metabolism:
Galcanezumab is metabolized through typical pathways for monoclonal antibodies, involving catabolism via proteolytic enzymes into small peptides and amino acids. This metabolism occurs primarily within the reticuloendothelial system and does not involve hepatic cytochrome P450 enzymes, reducing the potential for metabolic drug interactions. The absence of cytochrome P450 involvement suggests that galcanezumab metabolism is unaffected by enzymatic induction or inhibition commonly seen with small molecule drugs.

Elimination:
The elimination half-life of galcanezumab averages approximately 27 days, supporting its monthly dosing regimen. Clearance is mainly via proteolytic catabolism with no renal excretion of intact drug. Due to its large size, renal elimination is negligible. The prolonged half-life reflects slow catabolic processes and recycling via the neonatal Fc receptor (FcRn), which protects IgG antibodies from rapid degradation. Steady-state concentrations are generally achieved after 3 to 4 months of repeated dosing. No dose adjustments are recommended for patients with renal or hepatic impairment given the catabolic elimination pathway.

Dosage Forms

Available Dosage Forms:
- Emgality is supplied as single-dose prefilled injection devices:
- Prefilled pen containing 120 mg/mL solution
- Prefilled syringe available in two concentrations: 100 mg/mL and 120 mg/mL solutions
These delivery forms facilitate subcutaneous self-administration in various injection sites.

Dosages for Adults and Adolescents:
- For migraine prophylaxis:
- Initial loading dose: 240 mg subcutaneously (administered as two consecutive 120 mg injections)
- Maintenance dose: 120 mg subcutaneously once monthly
- For episodic cluster headache treatment:
- Initial dose: 300 mg subcutaneously (administered as three consecutive 100 mg injections) at the onset of the cluster period
- Maintenance dose: 300 mg subcutaneously once monthly until the end of the cluster period

Specific Patient Populations:
- Pediatric use: Emgality is not approved for use in patients under 18 years of age.
- Renal and hepatic impairment: No dosage adjustment is required due to proteolytic elimination and negligible metabolic involvement.
- Special populations such as pregnant or breastfeeding women require careful risk-benefit evaluation, as safety data remain limited.
- Injection sites include abdomen, thigh, upper arm, or buttocks, avoiding areas of skin that are tender, bruised, red, or hard.
- Missed doses should be administered as soon as possible and then continue with the monthly schedule from that date.

Mechanism Of Action

Emgality (galcanezumab) is a humanized monoclonal antibody that specifically binds to the calcitonin gene-related peptide (CGRP) ligand, neutralizing its biological activity. CGRP is a neuropeptide widely distributed in the central and peripheral nervous systems, known to play a critical role in the pathophysiology of migraine and cluster headaches through vasodilation and transmission of nociceptive signals.

By binding CGRP, galcanezumab prevents CGRP from activating its receptor on vascular smooth muscle cells and neurons, thereby inhibiting neurogenic inflammation, vasodilation, and pain transmission involved in migraine pathogenesis. This blockade results in a reduction of migraine frequency and severity by modulating trigeminovascular system activity.

The antibody’s humanized IgG4 structure allows for effective binding with high specificity and affinity to the CGRP ligand, minimizing off-target effects. Unlike small molecule CGRP receptor antagonists, Emgality binds directly to the ligand rather than the receptor, providing a mechanism distinct from receptor antagonists and contributing to its efficacy and safety profile.

Clinical studies have demonstrated that Emgality significantly reduces the number of migraine days per month and frequency of cluster headache attacks, confirming the importance of CGRP in these disorders. The prolonged half-life supports sustained inhibition of CGRP-mediated pathways, making monthly dosing effective in chronic management.

Pharmacological Actions

Selective antagonism of calcitonin gene-related peptide (CGRP) ligand activity.
Inhibition of CGRP-induced vasodilation in cerebral and extracerebral blood vessels.
Modulation of trigeminovascular system to reduce neurogenic inflammation.
Reduction in peripheral and central sensitization associated with migraine pathogenesis.
Prevention of CGRP-mediated nociceptive signal transmission in pain pathways.
Long-acting monoclonal antibody with sustained biological activity.
Minimal interaction with other receptors or enzymes, leading to a favorable safety profile.
Reduction of frequency and severity of migraine attacks by interfering with key neuropeptide signaling.

Therapeutic Or Clinical Uses

Preventive treatment of migraine headaches in adults.
Treatment of episodic cluster headaches in adults.
Reduction in number of monthly migraine days in patients with episodic or chronic migraine.
Decreasing frequency of cluster headache attacks during cluster periods.
Management option for patients who have not responded to conventional migraine prophylactics.
Adjunct therapy for migraine and cluster headache patients to improve quality of life.
Potential use in reducing disability associated with recurrent headache disorders.
Useful in migraine prophylaxis with a favorable and well-tolerated safety profile.

Side Or Adverse Effects

Injection site pain, the most commonly reported adverse effect.
Redness, itching, and irritation at the site of injection.
Potential hypersensitivity reactions including rash and urticaria.
Serious allergic reactions such as anaphylaxis, although rare, can occur.
Injection site swelling and erythema.
Mild to moderate nausea in some patients post-injection.
Fatigue and dizziness reported in isolated cases.
Rare events of hypersensitivity may manifest days after administration.
No significant impacts on weight or systemic laboratory parameters documented.
Generally well tolerated with low incidence of serious adverse events.

Precautions

Not approved for use in patients younger than 18 years of age.
Avoid use in patients with known hypersensitivity to galcanezumab or any component of the formulation.
Inform healthcare providers about all allergies prior to initiating therapy.
Monitor for signs of allergic reactions following injection, especially in initial treatment phases.
Use with caution during pregnancy; assess risk-benefit due to limited human data.
Breastfeeding mothers should consult healthcare provider due to unknown excretion and effects in milk.
Store injections in refrigeration; avoid freezing or exposure to excessive heat.
Proper injection technique and site rotation should be maintained to minimize local adverse effects.
Patients should be educated on recognizing signs of hypersensitivity or injection site infections.
Patients with significant cardiovascular history should use under medical supervision, although no direct cardiovascular contraindications exist.

Warnings

Potential for severe allergic reactions including anaphylaxis; seek emergency care if symptoms develop.
Delayed hypersensitivity reactions have been reported and may occur several days post-injection.
Do not use if the medication appears discolored, cloudy, or contains particulate matter.
Avoid injecting into skin that is bruised, hard, red, or tender to reduce injection site complications.
Store at recommended temperatures; do not freeze or shake the product to maintain drug integrity.
If a dose is missed, administer as soon as possible without doubling doses on the same day.
Pregnancy and lactation safety not established; exercise caution and clinical judgment.
Not indicated for the acute treatment of migraine attacks or in patients under 18 years.
Patients should disclose all concomitant medications to assess interaction potential.
Keep out of reach of children and unauthorized individuals.

Contraindication

Known hypersensitivity or allergic reaction to galcanezumab or any excipients in Emgality.
Use in pediatric population under 18 years of age is contraindicated due to lack of safety data.
Patients with prior severe allergic reactions to monoclonal antibodies should avoid use unless benefits outweigh risks.

Drug Interactions

No significant drug-drug interactions mediated by cytochrome P450 enzymes are expected due to proteolytic metabolism.
Potential interactions with concurrent medications have not been fully characterized; clinical monitoring is recommended.
No evidence suggests inhibition or induction of common drug-metabolizing enzymes or transporters.
May be used concomitantly with other migraine therapies, but clinical judgment is advised.
No interactions with over-the-counter vitamins or herbal supplements have been established.
Drugs that alter immune system function theoretically could affect monoclonal antibody efficacy or tolerance.
No known interactions that necessitate dose adjustment of Emgality or other concomitant medications.
Caution advised when co-administering with other injectable biologics due to potential additive immunosuppressive effects.

Preparations Of The Drug

Available as single-dose prefilled pen containing 120 mg/mL solution for subcutaneous injection.
Available as single-dose prefilled syringes with concentrations of 100 mg/mL and 120 mg/mL solutions.
Formulated with inactive ingredients including L-histidine, L-histidine hydrochloride monohydrate, Polysorbate 80, Sodium Chloride, and Water for Injection, USP.
Supplied in cartons protecting from light and temperature changes; do not freeze or shake.
Prefilled administration devices designed for patient self-injection after proper training.
Storage recommended in refrigerator at 2°C to 8°C (36°F to 46°F); can be kept at room temperature up to 30°C (86°F) for a maximum of 7 days.
Each prefilled syringe or pen is single-use; discard after one use regardless of leftover medication.
Includes detailed Instructions for Use to ensure proper handling, storage, and administration techniques.